Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Avantor, Inc. for alleged violations of federal securities laws, encouraging affected investors to contact them before the December 29, 2025 deadline for lead plaintiff applications in a federal securities class action [2][4]. Group 1: Allegations Against Avantor - The complaint alleges that Avantor and its executives made false and misleading statements regarding the company's competitive positioning and failed to disclose the negative impacts of increased competition [4]. - Specific claims include that Avantor's competitive position was weaker than represented, and that the company was adversely affected by heightened competition [4]. Group 2: Financial Performance and Stock Impact - During the class period, Avantor's executives misled investors about the company's competitive standing, assuring them of strong performance despite increasing competition [5]. - On April 25, 2025, Avantor reported disappointing Q1 2025 results, cutting its guidance and announcing the resignation of CEO Michael Stubblefield, leading to a stock price drop of over 16.5% [6]. - Following further disappointing results in Q2 2025, including a projected organic revenue growth of -2% to 0%, the stock fell by more than 15% on August 1, 2025 [7][8]. - In Q3 2025, Avantor reported a net loss of $712 million and -5% organic revenue growth, attributing the poor performance to competitive pressures, resulting in a stock decline of over 23% [9][10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Gauzy Ltd. following significant financial distress and insolvency proceedings involving its French subsidiaries, which has led to a drastic decline in the company's stock price [2][4][5]. Group 1: Company Financial Distress - Gauzy Ltd. announced that three of its French subsidiaries are undergoing Redressement Judiciaire, a form of insolvency proceedings, which indicates they lack the financial means to meet their debts [4][5]. - The initiation of these proceedings has triggered a default under Gauzy's existing senior secured debt facilities, raising concerns about the company's financial stability [5]. - Following the announcement, Gauzy's share price plummeted by $2.00, nearly 50%, closing at $2.02 on November 17, 2025, amid unusually high trading volume [6]. Group 2: Legal Actions and Investor Rights - Investors who purchased securities in Gauzy between March 11, 2025, and November 13, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi, as a federal securities class action has been filed against the company [1][2]. - The deadline for investors to seek the role of lead plaintiff in the class action is February 6, 2026 [2]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Gauzy's conduct [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against F5, Inc. due to allegations of federal securities law violations related to misleading statements about the company's security capabilities and a significant security breach impacting its operations and market performance [2][4]. Group 1: Company Overview - F5, Inc. is a publicly traded company listed on NASDAQ under the ticker FFIV [2]. - The company has faced significant challenges due to a security breach affecting its key offerings, particularly its highest revenue product, BIG-IP [4][5]. Group 2: Legal Proceedings - A federal securities class action has been filed against F5, with a deadline of February 17, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 3: Financial Impact - Following the announcement of the fourth quarter fiscal year 2025 results, F5 reported significantly below-market growth expectations for fiscal 2026, attributing this to the security breach [5]. - The company's stock price fell from $290.41 per share on October 27, 2025, to $258.76 per share on October 28, 2025, marking a decline of 10.9% in just two days [6].

Core Viewpoint - A securities class action lawsuit has been filed against Coupang, Inc. for alleged inadequate cybersecurity measures that led to a data breach affecting sensitive customer information [1][2] Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of all individuals or entities that purchased Coupang securities between August 6, 2025, and December 16, 2025 [1] - The complaint alleges that a former employee accessed sensitive customer information for nearly six months without detection, indicating inadequate cybersecurity protocols [2] - It is claimed that the company faced increased regulatory and legal scrutiny due to this data breach, and that the defendants failed to report the breach in compliance with SEC reporting rules [2] Group 2: Investor Information - Investors who acquired Coupang shares are encouraged to contact the law firm before the lead plaintiff motion deadline on February 17, 2026 [3] - The lead plaintiff will represent other class members in directing the litigation [3]

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gauzy Ltd. (NASDAQ: GAUZ) between March 11, 2025 and November 13, 2025, both dates inclusive (the “Class Period”), of the important February 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Gauzy securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Primo Brands To Contact Him Directly To Discuss Their Options If you purchased or acquired securities: (a) the common stock of Primo Water between June 17, 2024 through November 8, 2024, inclusive, and/or (b) the common stock of Primo Brands between November 11, 2024 through November 6, 2025, inclusive (collectively, the “Class Period”) and would like to discuss your legal rights, call Faruqi & ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Avantor, Inc. due to allegations of misleading statements regarding the company's competitive positioning and financial performance during a specified period [1][3]. Group 1: Allegations and Misleading Statements - The complaint alleges that Avantor and its executives violated federal securities laws by making false and misleading statements about the company's competitive position and failing to disclose the negative impacts of increased competition [3]. - During an earnings call on July 26, 2024, Avantor's then-CEO Michael Stubblefield assured investors of the company's strong competitive position, despite evidence suggesting otherwise [4]. Group 2: Financial Performance and Stock Impact - Investors became aware of the adverse effects of competition on Avantor's business on April 25, 2025, when the company reported disappointing Q1 2025 results, leading to a stock price decline of over 16.5% [5]. - On August 1, 2025, Avantor reported further disappointing Q2 2025 results, including a projected organic revenue growth of -2% to 0%, resulting in a stock price drop of more than 15% [6]. - The company reported weak Q3 2025 results on October 29, 2025, including a net loss of $712 million attributed to competitive pressures, causing the stock price to decline by over 23% [7]. Group 3: Legal Proceedings and Class Action - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Avantor is December 29, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of violations of federal securities laws, encouraging affected investors to discuss their legal options before the January 9, 2026 deadline for lead plaintiff applications in a class action lawsuit [1][3]. Group 1: Allegations Against Telix Pharmaceuticals - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates [3]. - It is claimed that the company overstated the quality of its supply chain and partners, leading to materially false statements about its business and operations [3]. - The lawsuit asserts that when the true details emerged, investors suffered damages due to the misleading information [3]. Group 2: Impact of Regulatory Actions - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, which caused the price of its American Depositary Shares (ADSs) to drop by over 13% in two trading sessions [4]. - On August 28, 2025, Telix announced receiving a Complete Response Letter from the U.S. Food and Drug Administration regarding its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package, leading to a further decline of over 21% in ADS price over two trading sessions [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Alexandria To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Alexandria between January 27, 2025 and October 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 17, 2025 /PRNewswire/ -- Faru ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Baxter common stock during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious malfunctions and risks to patient safety [5] - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [5] - The firm claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]